SEHK:1345

Stock Analysis Report

China Pioneer Pharma Holdings

Executive Summary

China Pioneer Pharma Holdings Limited, an investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People’s Republic of China.


Snowflake Analysis

Flawless balance sheet and undervalued.


Similar Companies

Share Price & News

How has China Pioneer Pharma Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1345's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.3%

1345

1.0%

HK Healthcare

0.2%

HK Market


1 Year Return

-33.3%

1345

-41.9%

HK Healthcare

-22.0%

HK Market

Return vs Industry: 1345 exceeded the Hong Kong Healthcare industry which returned -42.7% over the past year.

Return vs Market: 1345 underperformed the Hong Kong Market which returned -21.6% over the past year.


Shareholder returns

1345IndustryMarket
7 Day6.3%1.0%0.2%
30 Day-20.0%-17.4%-10.8%
90 Day-1.4%-28.1%-16.5%
1 Year-27.3%-33.3%-40.5%-41.9%-19.1%-22.0%
3 Year-75.0%-78.5%-48.9%-51.9%-3.7%-13.4%
5 Year-86.5%-89.5%-54.4%-58.5%-15.2%-28.8%

Price Volatility Vs. Market

How volatile is China Pioneer Pharma Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is China Pioneer Pharma Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1345 (HK$0.68) is trading below our estimate of fair value (HK$6.1)

Significantly Below Fair Value: 1345 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1345 is good value based on its PE Ratio (7.2x) compared to the Healthcare industry average (13.6x).

PE vs Market: 1345 is good value based on its PE Ratio (7.2x) compared to the Hong Kong market (9.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1345's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1345 is good value based on its PB Ratio (0.7x) compared to the HK Healthcare industry average (1.2x).


Next Steps

Future Growth

How is China Pioneer Pharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Pioneer Pharma Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has China Pioneer Pharma Holdings performed over the past 5 years?

-14.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1345 has high quality earnings.

Growing Profit Margin: 1345's current net profit margins (8%) are higher than last year (5.2%).


Past Earnings Growth Analysis

Earnings Trend: 1345's earnings have declined by -14.9% per year over the past 5 years.

Accelerating Growth: 1345's earnings growth over the past year (23.7%) exceeds its 5-year average (-14.9% per year).

Earnings vs Industry: 1345 earnings growth over the past year (23.7%) exceeded the Healthcare industry 7%.


Return on Equity

High ROE: 1345's Return on Equity (9.1%) is considered low.


Next Steps

Financial Health

How is China Pioneer Pharma Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 1345's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥363.1M).

Long Term Liabilities: 1345's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥7.5M).


Debt to Equity History and Analysis

Debt Level: 1345's debt to equity ratio (4.3%) is considered satisfactory.

Reducing Debt: 1345's debt to equity ratio has reduced from 50.1% to 4.3% over the past 5 years.

Debt Coverage: 1345's debt is well covered by operating cash flow (574.6%).

Interest Coverage: 1345 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: 1345 has a high level of physical assets or inventory.

Debt Coverage by Assets: 1345's debt is covered by short term assets (assets are 24.5x debt).


Next Steps

Dividend

What is China Pioneer Pharma Holdings's current dividend yield, its reliability and sustainability?

5.15%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: 1345's dividend (5.15%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.57%).

High Dividend: 1345's dividend (5.15%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.33%).


Stability and Growth of Payments

Stable Dividend: 1345 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 1345 has only been paying a dividend for 6 years, and since then payments have fallen.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (37.3%), 1345's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Chunyi Luo (50yo)

1.25s

Tenure

Mr. Chunyi Luo has been CEO and Director at China Pioneer Pharma Holdings Ltd since January 22, 2019. He has extensive experience in corporate management and banking. Prior to joining the Group, he had ser ...


Leadership Team

NamePositionTenureCompensationOwnership
Xinzhou Li
Chairmanno dataCN¥1.74m2.95% CN¥24.6m
Chunyi Luo
CEO & Director1.25yrsno datano data
Yi Xue
Chief Financial Officer3.33yrsno datano data
Lei Qu
Director of Administration Affairs and Human Resources 3.33yrsno datano data
Chi Shing Luk
Executive Director0.33yrno datano data
Yu Fu
Joint Company Secretary1.08yrsno datano data
Ka Man Ng
Joint Company Secretary1.08yrsno datano data
Tao Wang
General Manager of Easyhaler & Neutrophase Business Unit5.58yrsno datano data

1.3yrs

Average Tenure

48yo

Average Age

Experienced Management: 1345's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Xinzhou Li
Chairmanno dataCN¥1.74m2.95% CN¥24.6m
Chunyi Luo
CEO & Director1.25yrsno datano data
Chi Shing Luk
Executive Director0.33yrno datano data
Mijia Wu
Non-Executive Director6.5yrsCN¥204.00kno data
Chi Hung Wong
Independent & Non-Executive Director6.5yrsCN¥298.00kno data
Lap Keung Hui
Non-Executive Directorno datano datano data
Hong Zhang
Independent Non-Executive Director1.25yrsno datano data
Guoguang Xiao
Independent Non-Executive Director0.083yrno datano data

1.3yrs

Average Tenure

53yo

Average Age

Experienced Board: 1345's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

China Pioneer Pharma Holdings Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China Pioneer Pharma Holdings Limited
  • Ticker: 1345
  • Exchange: SEHK
  • Founded: 1996
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: HK$831.291m
  • Shares outstanding: 1.22b
  • Website: https://www.pioneer-pharma.com

Number of Employees


Location

  • China Pioneer Pharma Holdings Limited
  • No.15, Lane 88 Wuwei Road
  • Putuo District
  • Shanghai
  • 200331
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1345SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDNov 2013
14PDB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2013

Biography

China Pioneer Pharma Holdings Limited, an investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People’s Republic of China. It has a portfolio of pharmaceutical products, such as ophthalmology, pain management, cardiovascular, respiratory, gastroenterology, immunology, gynecology, and other therapeutic areas, as well as medical devices, including ophthalmology, orthopedics, odontology, and wound care products. The company sells its products to hospitals and other medical institutions, and pharmacies. It also leases ancillary tools and accessories; and sells dental devices. In addition, China Pioneer Pharma Holdings Limited engages in the sale of imported in-licensed prescription products. The company was founded in 1996 and is headquartered in Shanghai, the People’s Republic of China. China Pioneer Pharma Holdings Limited is a subsidiary of Pioneer Pharma (BVI) Co., Ltd. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/03 13:03
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.